Benign prostatahyperplasi (BPH)
Sist oppdatert: Sist revidert:
Sist revidert av:Wolfgang Lilleby
Definisjon:
Forstørret prostata som følge av økt vekst av godartet kjertelvev
Forekomst:
BPH rammer 10% av menn under 40 år og 70-80% av alle menn over 60 år
Symptomer:
Obstruktive vannlatingsproblemer med nedsatt kraft på strålen, hesitasjon, etterdrypp og hyppig vannlatning dag og natt. BPH er ikke nødvendigvis symptomgivende
Funn:
Vanligvis ikke noen spesielle funn ved klinisk undersøkelse. Prostata kan kjennes forstørret ved rektal undersøkelse. Ved betydelig resturin kan urinblæren palperes
Diagnostikk:
Måling av residualurin og urinstrømshastighet kan være nyttig. Utred nyrefunksjon og gjør urinundersøkelse, men tilstanden påvirker normalt ikke disse. PSA-test kan være aktuelt. CT, ultralyd eller cystoskopi er aktuelle undersøkelser ved behov for utredning
Behandling:
Symptomer som forringer livskvaliteten behandles og ev. komplikasjoner forebygges. Behandlingen strekker seg fra informasjon og råd og en avventende observasjon, via medikamentell behandling, til kirurgi
- Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 361: 1359-67. PubMed
- Sarma AV, St Stauver JL, Hollingsworth JM, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology 2012; 79: 102-8. PubMed
- D'Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA 2014; 312:535. www.ncbi.nlm.nih.gov
- Schou J, Poulsen AL, Nordling J. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol. 1993;27(4):489-92. PMID: 7512747. PubMed
- Pearson R, Williams PM. Common questions about the diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2014 Dec 1;90(11):769-774. .
- McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803.
- Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248-57. New England Journal of Medicine
- Folkestad B, Spångberg A. Timed micturition and maximum urinary flow rate in randomly selected symptom-free males. Scand J Urol Nephrol 2004; 38: 136-42. pmid:15204399 PubMed
- Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels. An evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-2700. Journal of the American Medical Association
- Bjerklund Johansen TE. Medikamenter mot symptomgivende godartet prostataforstørrelse. Tidsskr Nor Lægeforen 2002; 122: 2544-5. PubMed
- Nedre urinveissymptomer hos eldre menn. Norsk urologisk forenings anbefalinger for allmennleger 2014.
- Dahm P, Brasure M, MacDonald R, et al. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol 2017; 71:570. PubMed
- Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009; 56: 534-41. PubMed
- Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003. PubMed
- Welk B, McArthur E, Fraser L-A, et al. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ 2015; 351: h5398. doi:10.1136/bmj.h5398 DOI
- Toren P, Margel D, Kulkarni G, et al. Effect of dutasteride on clinicial progression of benign prostatic hyperplasia in asymptomatic men with elnarged prostate: a post hoc analysis of the REDUCE study. BMJ 2013; 346: f2109. BMJ (DOI)
- Park T, Choi JY. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.. World J Urol 2014; 32(4): 1093-105. pmid:24500194 PubMed
- Robinson D, Garmo H, Bill-Axelson A, et al. Use of a 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: natiowide, population based case-control study. BMJ 2013; 346: f3406. BMJ (DOI)
- Wei L, Lai EC-C, Kao-Yang Y-H, et al. CCBY Open access Research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ 2019; 365: l1204. doi:10.1136/bmj.l1204 DOI
- Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol 2022; 8: 1019-26. pmid:35587340 PubMed
- Baboudjian M, Gondran-Tellier B, Dariane C, et al. Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality A Systematic Review and Meta-analysis. JAMA Oncol 2023. pmid:37079318 PubMed
- Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol. 2013;190(6):2153–2160.
- Lenfant L, Pinar U, Roupret M, et al. Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: An updated systematic review and meta-analysis. J Urol 2023 Feb; 209:314. PMID: 36395428 PubMed
- van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: Efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013. pmid: 23932438 PubMed
- Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol 2013; 190: 2153-60. pmid:23727412 PubMed
- Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic reviews 2012; 12: CD001423. The Cochrane Library
- Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al.. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018 Dec;122(6):1049-1065. Epub 2018 Jun 6. PMID: 29694707.
- Huang SW, Tsai CY, Tseng CS, et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. BMJ 2019 ; 367: l5919. PMID: 31727627 PubMed
- Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: A systematic review and meta-analysis. Eur Urol. 2014 Nov 15 . doi:10.1016/j.eururo.2014.10.031 DOI
- Chughtai B, Simma-Chiang V, Kaplan SA. Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms. Curr Urol Rep. 2014 ;15:434. doi: 10.1007/s11934-014-0434-1.
- Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999, 83:227.
- Glazener C, Boachie C, Buckley B, et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy og transurethral resection of the prostate (MAPS): two parallell randomised controlled trials. Lancet 2011; 378: 328-37. PubMed
- Andersen M, Walter S. Mikrobølgetermoterapi for benign prostatahyperplasi. Gennemgang af et Cochrane-review. Ugeskr Læger 2009; 171: 2281. Ugeskrift for Læger
- Hoffman RM, Monga M, Elliott SP, MacDonald R, Langsjoen J, Tacklind J, Wilt TJ. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD004135. DOI: 10.1002/14651858.CD004135.pub3. DOI
- Green Z, Westwood J, Somani BK. What's New in Rezum: a Transurethral Water Vapour Therapy for BPH. Curr Urol Rep 2019; 20: 39. pmid:31152253 PubMed
- Dixon C, Cedano ER, Pacik D, et al. Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urology 2015; 86: 1042-7. pmid:26216644 PubMed
- Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802-8813. PubMed
- Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary Retention in Adults: Evaluation and Initial Management. Am Fam Physician 2018; 98(8): 496-503. pmid:30277739 PubMed
- Chang RT, Kirby R, Challacombe BJ. Is there a link between BPH and prostate cancer? Practitioner. 2012 Apr;256(1750):13-6, 2. PMID: 22792684. PubMed
- Wolfgang Lilleby, spesialist i onkologi
- Peter D. Jost, spesialist i allmennmedisin, redaktør NEL
Tidligere fagmedarbeidere
- Trygve Talseth, spesialist urologi, dr. med
- Svein Z. Bratland, spesialist i allmennmedisin, Sandviken Legesenter, Bergen, og seniorrådgiver i Statens helsetilsyn, Oslo